Biovian and 3P Biopharmaceuticals have created a new pan-European CDMO, dubbed 3PBIOVIAN.
Finnish Biovian Oy and Pamplona-based 3P Biopharmaceuticals Srl have joined forces to build a pan-European Contract Development and Manufacturing Organization (CDMO) named 3PBiovian. Backed by their common shareholder, Keensight Capital, the companies combine their expertise in the areas of viral vector production, microbial production of recombinant proteins, plasmid DNA (Biovian) and process development and GMP-compliant manufacturing of biologics and cell therapy products.
The combined Group, named 3PBIOVIAN, will offer end-to-end development and manufacturing services for all protein expression systems and viral vectors from preclinical to clinical development and commercial production. Leveraging a joint 40-year track record, expertise, capabilities, and financial strength, the Group will position itself as a pan-European biologics CDMO, with gross sales above €75m.
Biovian and 3P Biopharmaceuticals have each delivered consistent double-digit growth historically, and this organic growth will underpin the development of the combined business going forward. With over 500 professionals and operating across manufacturing facilities of 15,800 square meters, the group is now positioned to address market demands.
3PBiovian SA activities will span across multiple platforms (microbial and mammalian expression, adenoviruses, adeno-associated viruses, cell therapy and plasmids) and offers enhanced production scale flexibility via a diverse range of bioreactor sizes.
Dámaso Molero Sánchez (former 3P CEO) will serve as Group CEO supported by Deputy CEO Antti Nieminen (former Biovian CEO), Heidi Suuronen as CFO and Elena Erroba as CCO (Chief Commercial Officer).